Belimumab Therapy for Systemic Lupus Erythematosus and Lupus Nephritis

Introduction to Belimumab Therapy

The patient's SELENA-SLEDAI score decreased from 12 to 4 while on belimumab therapy, indicating significant clinical improvement, according to the Kidney International journal 1, 2
The patient has already failed or had intolerance to multiple therapies, making belimumab an important treatment option, as noted in the Kidney International journal 2

Discontinuation of successful treatment regimens in patients with severe SLE carries significant risk of disease flares and potential organ damage, as reported in Arthritis and Rheumatology and Arthritis care & research journals 3, 4
The 2024 KDIGO Clinical Practice Guideline for Lupus Nephritis supports the use of belimumab as part of maintenance therapy, noting that "efficacy benefit associated with belimumab treatment was maintained with no safety concerns", according to the Kidney International journal 1, 2
The American College of Rheumatology guidelines recommend continuing belimumab in patients with severe SLE, particularly those with nephritis, due to the risk of disease flares if therapy is interrupted, as stated in Arthritis and Rheumatology and Arthritis care & research journals 3, 4, 5

Most patients with lupus nephritis require at least 3 years of maintenance immunosuppression therapy, as noted in the Kidney International journal 1, 2
Premature discontinuation could lead to disease flare and organ damage, particularly in patients with severe manifestations like lupus nephritis, according to Arthritis and Rheumatology and Arthritis care & research journals 3, 4

The European League Against Rheumatism (EULAR) guidelines recommend belimumab for patients with inadequate response to standard-of-care, defined as residual disease activity not allowing tapering of glucocorticoids and/or frequent relapses, which applies to this patient with persistent symptoms despite standard therapy 6
The patient meets the EULAR guideline criteria for belimumab initiation, having documented positive ANA and inadequate response to hydroxychloroquine and mycophenolate mofetil 6

The EULAR 2019 recommendations give belimumab a 1a/A level recommendation (highest quality evidence) for patients with inadequate response to hydroxychloroquine and immunosuppressives 6
The American College of Rheumatology (ACR) 2022 perioperative guideline emphasizes the risk of disease flares and potential organ damage with discontinuation of successful treatment regimens in patients with severe SLE, supporting the initiation of effective therapy like belimumab when standard treatments fail 7
The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Lupus Nephritis Guideline notes belimumab's efficacy benefit and no safety concerns in long-term use, supporting its use as maintenance therapy for at least 3 years in appropriate patients 8

The EULAR guidelines emphasize that immunomodulating/immunosuppressive agents like belimumab can expedite the tapering/discontinuation of glucocorticoids, which is relevant for this patient who is not currently on systemic glucocorticoids 6

The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines recommend that patients treated with triple immunosuppressive regimens, including belimumab, should continue with triple therapy as maintenance 9, 10, 11, 12
Patients achieving complete response on belimumab-containing regimens have lower rates of adverse kidney outcomes and better preserved kidney function compared to standard therapy alone 9, 10

The BLISS-LN trial demonstrated sustained efficacy of belimumab through 104 weeks, with an open-label extension showing maintained benefit at 128 weeks and no safety concerns 9, 10, 11, 12
Belimumab-treated patients had fewer lupus nephritis flares and slower decline in kidney function, benefits that would be lost with discontinuation 13

The open-label extension of BLISS-LN (128 weeks total) showed no increase in adverse events with prolonged belimumab use 9, 10
Belimumab add-on therapy did not increase the incidence of adverse events compared to standard therapy alone 13

The KDIGO 2024 guidelines explicitly state that most patients with lupus nephritis require ≥3 years of maintenance immunosuppression after achieving response 10, 11, 12
The American College of Nephrology recommends continuing belimumab in patients with lupus nephritis who have achieved a complete renal response, as defined by KDIGO criteria 9